Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Quarterly Earnings Results

Monte Rosa Therapeutics (NASDAQ:GLUE) announced its quarterly earnings results on Thursday. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05), FiscalAI reports. Monte Rosa Therapeutics had a negative net margin of 560.85% and a negative return on equity of 48.30%. The firm had revenue of $8.97 million during the quarter, compared to analyst estimates of $12.91 million.

Monte Rosa Therapeutics Stock Up 1.1%

Shares of Monte Rosa Therapeutics stock traded up $0.17 during trading on Friday, hitting $15.88. 1,031,388 shares of the stock traded hands, compared to its average volume of 1,631,805. The company has a fifty day moving average price of $20.53 and a two-hundred day moving average price of $19.35. Monte Rosa Therapeutics has a twelve month low of $4.12 and a twelve month high of $25.77.

Insider Buying and Selling at Monte Rosa Therapeutics

In related news, insider Sharon Townson sold 6,000 shares of the business’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $23.31, for a total transaction of $139,860.00. Following the transaction, the insider owned 67,845 shares of the company’s stock, valued at approximately $1,581,466.95. The trade was a 8.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Filip Janku sold 5,407 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $24.50, for a total transaction of $132,471.50. Following the transaction, the insider owned 60,612 shares in the company, valued at approximately $1,484,994. The trade was a 8.19% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 81,778 shares of company stock valued at $1,768,581. 6.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in GLUE. Russell Investments Group Ltd. bought a new position in shares of Monte Rosa Therapeutics in the third quarter valued at approximately $32,000. BNP Paribas Financial Markets grew its position in Monte Rosa Therapeutics by 88.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,733 shares of the company’s stock worth $72,000 after acquiring an additional 4,565 shares during the last quarter. Prelude Capital Management LLC acquired a new stake in Monte Rosa Therapeutics during the 3rd quarter valued at $76,000. Lazard Asset Management LLC increased its holdings in Monte Rosa Therapeutics by 42.9% during the 2nd quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock valued at $48,000 after purchasing an additional 3,262 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV bought a new position in Monte Rosa Therapeutics in the 4th quarter valued at $172,000. 79.96% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, July 28th. Guggenheim dropped their price objective on Monte Rosa Therapeutics from $35.00 to $28.00 and set a “buy” rating on the stock in a research note on Friday. Wells Fargo & Company cut their price objective on Monte Rosa Therapeutics from $29.00 to $27.00 and set an “overweight” rating for the company in a report on Friday. Wedbush lowered their target price on Monte Rosa Therapeutics from $37.00 to $27.00 and set an “outperform” rating on the stock in a report on Monday, August 3rd. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Monte Rosa Therapeutics in a research report on Monday, July 27th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Monte Rosa Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.50.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.